|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Pfizer |
|---|---|
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00150332 |
Purpose
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
| Condition | Intervention | Phase |
|---|---|---|
|
Infections, Nosocomial |
Drug: linezolid |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-Label, Multi-Center Trial |
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Japan | |
| Pfizer Investigational Site | |
| Fukuoka, Japan, 813-0025 | |
| Pfizer Investigational Site | |
| Fukuoka, Japan, 811-0213 | |
| Pfizer Investigational Site | |
| Hiroshima, Japan, 734-8530 | |
| Pfizer Investigational Site | |
| Hiroshima, Japan, 730-8619 | |
| Pfizer Investigational Site | |
| Kyoto, Japan, 615-8256 | |
| Pfizer Investigational Site | |
| Nagasaki, Japan, 852-8501 | |
| Pfizer Investigational Site | |
| Okayama, Japan, 700-8505 | |
| Pfizer Investigational Site | |
| Okayama, Japan, 703-8275 | |
| Japan, Chiba | |
| Pfizer Investigational Site | |
| Kamogawa, Chiba, Japan, 296-0041 | |
| Japan, Fukuoka | |
| Pfizer Investigational Site | |
| Onga-gun, Fukuoka, Japan, 807-0051 | |
| Japan, Hokkaido | |
| Pfizer Investigational Site | |
| Sapporo, Hokkaido, Japan, 006-8555 | |
| Pfizer Investigational Site | |
| Sappopro, Hokkaido, Japan, 060-8648 | |
| Japan, Ibaraki | |
| Pfizer Investigational Site | |
| Moriya, Ibaraki, Japan, 302-0118 | |
| Japan, Kanagawa | |
| Pfizer Investigational Site | |
| Yokohama, Kanagawa, Japan, 236-0051 | |
| Japan, Nagasaki | |
| Pfizer Investigational Site | |
| Isahaya, Nagasaki, Japan, 854-8501 | |
| Japan, Okayama | |
| Pfizer Investigational Site | |
| Kurashiki, Okayama, Japan, 701-0912 | |
| Pfizer Investigational Site | |
| Kurashiki, Okayama, Japan | |
| Japan, Osaka | |
| Pfizer Investigational Site | |
| Suita, Osaka, Japan, 565-8565 | |
| Japan, Saitama | |
| Pfizer Investigational Site | |
| Iruma-gun, Saitama, Japan, 350-0495 | |
| Japan, Tokyo | |
| Pfizer Investigational Site | |
| Kodaira, Tokyo, Japan, 187-0004 | |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
| Study ID Numbers: | M12600067, A5951054 |
| Study First Received: | September 6, 2005 |
| Last Updated: | December 13, 2007 |
| ClinicalTrials.gov Identifier: | NCT00150332 History of Changes |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
|
Protein Synthesis Inhibitors Anti-Infective Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Enzyme Inhibitors Infection Linezolid Pharmacologic Actions Cross Infection |
